Biopharmaceuticals
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of genetic medicines designed to engage intracellular targets previously considered inaccessible. The company is advancing a robust portfolio of oligonucleotide programs for the treatment of neuromuscular and inherited retinal diseases, with lead programs targeting Duchenne muscular dystrophy (DMD) variants amenable to exon skipping. Entrada has partnered with Vertex Pharmaceuticals on VX-670, a clinical-stage program for myotonic dystrophy type 1 (DM1). The company expects a catalyst-rich 2026 with multiple clinical data readouts and four DMD programs anticipated to reach clinical stage by year-end.
Beta · Sourced from candidate reports
Be the first to share your experience with Entrada Therapeutics, Inc..
Your reply helps other candidates know what to expect.
